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LETTERS TO THE EDITOR
Compound Heterozygosity for Silent and Dominant Glycine
Substitution Mutations in COL7A1 Leads to a Marked
Transient Intracytoplasmic Retention of Procollagen VII and a
Moderately Severe Dystrophic Epidermolysis Bullosa
Phenotype
To the Editor:
Dystrophic epidermolysis bullosa (DEB) is caused by mutations
in the COL7A1 gene encoding collagen VII (Uitto and
Christiano, 1994; Hovnanian et al, 1997; Hammami-Hauasli
et al, 1998b), the major component of anchoring fibrils. In
autosomal dominant and recessive DEB, different phenotypes are
caused by heterozygous, compound heterozygous, or homozygous
mutations in COL7A1. Premature termination codon mutations
Figure 1. Moderately severe DEB phenotype in the proband, and
big toe nail dystrophy in individuals with maternal dominant
glycine substitution mutation in COL7A1. The proband, a now 10-y-
old girl (no. 2 in Fig. 3) who is compound heterozygous for the COL7A1
mutations G2316R and G2287R, demonstrated large scarring and ulcerating
plaques, loss of all the toe and finger nails, and mild fusion of left toes (A–
E). Her mother (G: no. 4 in Fig. 3), her maternal uncle (H: no. 5 in
Fig. 3), and her maternal grandmother (I: no. 6 in Fig. 3), who are
heterozygous for G2287R, showed nail deformity restricted to big toes
without any sings of skin fragility. All other family members without this
G2287R mutation have no signs of nail dystrophy, including the father
(F: no. 1 in Fig. 3) and the sister (no. 3 in Fig. 3) of the patient who are
heterozygous for G2316R silent glycine substitution.
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in both alleles lead to the most severe phenotype, the Hallopeau-
Siemens subtype, with lack of expression of collagen VII (Uitto
and Christiano, 1994; Hovnanian et al, 1997).
Among the different mutations, substitution of a glycine
residue in the triple helical collagenous domain by other, bulkier
amino acids present a biologically intriguing situation. Glycine
substitutions associated with dominant DEB interfere with folding
and secretion of collagen VII in a dominant negative manner
(Christiano and Uitto, 1996; Hammami-Hauasli et al, 1998b);
however, when combined with a normal allele, certain heterozyg-
ous glycine substitutions do not interfere with the biosynthesis
of collagen VII in this way and thus do not lead to a clinical
phenotype (Christiano et al, 1996; Shimizu et al, 1996; Hovnanian
et al, 1997). These mutations were termed silent glycine
substitutions. Combination of the silent glycine substitutions and
different COL7A1 mutations in the other allele have been
Figure 2. Procollagen VII was abundantly accumulated in the
intracytoplasm of epidermis at the age of 3 d. In the skin at 3 d
of age, abundant intracytoplasmic accumulation and weak linear BMZ
distribution of collagen VII was observed with antibodies to the NC-1
domain and to the triple helical domain (A). While BMZ was negative
with antibodies to the NC-2 domain, the abundant intracytoplasmic
retention was clearly positive (B), indicating that most of the retained
collagen was procollagen VII in which cleavage of NC-2 domain had not
occurred. In the skin at the age of 10 y, bright linear labeling of NC-1
and triple helical domain was found along BMZ, with an intensity
comparable with the normal control (C). In addition, careful observation
disclosed infrequent punctuate labeling within the epidermis, though far
less quantity compared with that of 3 d of age (C). The antibodies to the
NC-2 domain showed completely negative labeling at BMZ, whereas the
small infrequent punctuate material within the epidermis was positive (D),
indicating that the labeling was not background, but indeed represented
accumulation of procollagen VII.
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Figure 3. Identification of mutations G2316R and
G2287R in COL7A1. (A) Pedigree. The black areas
indicate the presence of the maternal mutation and the
shaded areas the presence of the paternal mutation. The
asterisk indicates family members with dystrophic toe
nails. (B) Conformation-sensitive gel electrophoresis
revealed heteroduplex bands in the polymerase chain
reaction products spanning exon 89 of individuals 1, 2,
and 3, and in the polymerase chain reaction products
including exon 87 of probands 2 and 4. (C) Direct
sequencing of the polymerase chain reaction products
disclosed a heterozygous G→A transition in exon 89 in
patient 2, her unaffected father 1, and her unaffected
sister 3. This sequence alteration led to the glycine
substitution G2316R (left panels). The dominant maternal
mutation was a heterozygous G→A transition in exon
87, which led to the glycine substitution G2287R (right
panels). (D) The paternal mutation created a Mae I site,
which cleaved the 331 bp polymerase chain reaction
product into two additional fragments of 140 bp and
125 bp (left panel). The maternal mutation G2287R was
verified by the loss of an Ava II site, which led to the
appearance of an uncleaved 404 bp fragment. This
mutation could also be found in the family members 5
and 6 (right panels). Genomic DNA of the elder son of
family member 5 was not available for testing.
shown to lead to various DEB phenotypes (Shimizu et al, 1996;
Hammami-Hauasli et al, 1998a; Terracina et al, 1998). In this
study, we explored the molecular basis of unusual DEB phenotype
similar to transient bullous dermolysis of the newborn (TBDN)
(Hashimoto et al, 1985).
The proband, a 10-year-old girl was born in September 1988
as the second child of nonconsanguineous healthy parents of
Japanese ethnic origin as described previously (Hatta et al, 1995).
At birth she presented with blisters on the entire integument
and on mucous membranes. Although the severity of the skin
condition has slightly decreased, the blister formation and
deformities of the nails have continued since then. At the age
of 10, she had large scarring and ulcerated plaques and lost all
her nails, and deformity of the left toes had developed (Fig 1A–E).
In order to study the expression and processing of procollagen
VII in the patient’s skin at the age of 3 d, 4 y, and 10 y, we used
three domain specific antibodies for indirect immunofluorescence
staining. Antibodies against the NC-1 (Leigh et al, 1987) and
the triple-helical domain (Bruckner-Tuderman et al, 1987)
recognize both procollagen VII and mature collagen VII. In
contrast, antibodies against the carboxyterminal NC-2 domain
(Bruckner-Tuderman et al, 1995) react only with procollagen
VII, which has not yet been processed to mature collagen. At
3 d of age, abundant intracytoplasmic accumulation and weak
linear BMZ distribution of collagen VII was observed in the
proband’s skin with antibodies to the NC-1 domain and to the
triple helical domain. While BMZ was negative with antibodies
to the NC-2 domain, the abundant intracytoplasmically retained
material was clearly positive, indicating that most of the
accumulating molecules were immature procollagen VII still
possessing the NC-2 domain (Fig 2). In the skin at the age
4 y and 10 y, bright linear labeling with antibodies to the
NC-1 and the triple helical domains was seen along BMZ. In
addition, infrequent punctuate labeling within the epidermis was
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positive with antibody to NC-2 domain, indicating that this
corresponded to residual accumulation of procollagen VII (Fig 2).
For mutation detection, genomic DNA from the patient and
her family members (Fig 3) were subjected to polymerase
chain reaction amplification and heteroduplex analysis and
dideoxynucleotide sequencing. The mutation screening identified
a heterozygous 6946G→A transition in exon 89 and a
heterozygous 6859G→A transition in exon 87 (Fig 3). Both
transitions substitute Arg for Gly and were designated as G2316R
and G2287R. The paternal mutation G2316R, also found in
the sister’s DNA, created a Mae I site (Fig 3D, left). The
maternal mutation G2287R eliminated an Ava II site (Fig 3D,
right). These sequence variations in exons 87 and 89 were not
found in 150 normal chromosomes, indicating that they did not
represent neutral polymorphisms. Screening of the entire coding
sequence and of all intron-exon borders of the COL7A1 gene
(Christiano et al, 1997) (Gene bank accession no. L23982) did
not reveal other nucleotide variations predicting changes in
collagen VII polypeptide sequence.
Although the mother was described as clinically unaffected
according to the previous report (Hatta et al, 1995), careful
clinical re-examination of all the family members disclosed the
presence of mild nail dystrophy restricted to both big toes,
without skin fragility, only in individuals heterozygous for
G2287R. These included the mother (Fig 1G: no. 4 in Fig 3),
the maternal uncle (Fig 1H: no. 5 in Fig 3), and the maternal
grandmother (Fig 1I: no. 6 in Fig 3) of the index patient.
Other family members without the G2287R mutation did not
show any sings of nail deformities or skin fragility. Therefore,
G2287R was interpreted as a dominantly inherited glycine
substitution mutation leading to a very mild phenotype, which
was overlooked at the time of the previous case report of this
patient (Hatta et al, 1995). Individuals carrying the paternal
mutation G2316R were clinically unaffected.
Recently we identified another dominant glycine substitution
mutation in COL7A1, G2251E, which caused only toe nail
dystrophy but not skin blistering when combined with a normal
allele (Hammami-Hauasli et al, 1998a); however, when compound
heterozygous with another silent glycine substitution in the
daughter of the index patient, the mutation led to an extensive
TBDN phenotype at birth. These results suggest the possibility
that some individuals who have been diagnosed as suffering
from idiopathic toe nail dystrophy of unknown origin without
skin fragility, might have been carriers of certain glycine
substitution mutations of COL7A1, such as G2251E or G2287R.
There are only two previously reported cases with TBDN in
which molecular defects have been identified. One is a COL7A1
splice site mutation in a TBDN child in a family with a
dominant pedigree (Christiano et al, 1997a). The second case is
a combination of silent glycine substitution (G1519D) and
dominant glycine substitution mutations (G2251E) (Hammami-
Hauasli et al, 1998a), a similar constellation as seen in the
present proband. The morphologic hallmark of TBDN, marked
transient accumulation of procollagen VII might represent mutant,
slowly secreted collagen VII molecules in postnatal skin where
the rate of collagen synthesis is high. Accordingly, transitory
blistering in TBDN has possibly more to do with the quantity
rather than quality of the abnormal collagen VII molecules.
Interestingly, the cessation of blister formation in TBDN roughly
coincides with a reduction in the biosynthesis rate and the
normalization of collagen VII deposition at the dermo–epidermal
junction, which is likely to indicate deposition of sufficiently
functional anchoring fibrils (Hammami-Hauasli et al, 1998a).
Although a combination of silent and dominant glycine
substitution mutations was also found in the above case with
TBDN (Hammami-Hauasli et al, 1998a), this is the first case in
which these combinations were shown to be associated with a
moderately severe classical DEB phenotype with marked transient
epidermal retention of procollagen VII at birth.
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